Home / Pharmaceuticals / Prostate Cancer Treatment Market By Treatment (Biological Therapy, Chemotherapy ) - Growth, Future Prospects And Competitive Analysis 2017 - 2025

Prostate Cancer Treatment Market By Treatment (Biological Therapy, Chemotherapy ) - Growth, Future Prospects And Competitive Analysis 2017 - 2025

Published: Apr 2017 | Report Code: 58402-04-17

This report on global prostate cancer treatment market studies various drugs used for treatment of prostate cancer along with pipeline analysis of upcoming potential drugs. According to National Cancer Institute approximately 12.9% of the men will be diagnosed with prostate cancer at some point during their lifetime. Prostate cancer can be diagnosed before the symptoms start by testing the prostate specific antigen (PSA) in a man’s blood or through the digital rectal exam (DRE). Currently there are a handful of players which are leading the prostate cancer treatment market, but in the future the competition will be more as several blockbuster prostate cancer therapeutic drugs are slated to go off-patent.

For the purpose of this study, the various treatment types studied include biological therapy which includes drugs like Enzalutamid (Xtandi), Abiraterone (Zytiga) and chemotherapy drugs like Docetaxel (Taxotere), Cabazitaxel (Jevtana); Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for prostate cancer treatment market comprises projected market sales of Phase III drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (biological or chemical), sponsor, depicted peak sales by leading market experts and other factors. Few prominent phase III drugs are ProstVac, Tasquinimod Active, ARN-509, ODM-201 and Yervoy etc.

The geographic segmentation of the global prostate cancer treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

Prostate Cancer Treatment Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Prostate Cancer Treatment Market Portraiture
2.2 Global Prostate Cancer Treatment Market, by Type of Treatment, 2016 (US$ Mn)
2.3 Global Prostate Cancer Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Prostate Cancer Treatment Market Analysis
3.1 Global Prostate Cancer Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing Prevalence of Prostate Cancer
3.2.1.2 Rise in aging population and public awareness of Prostate cancer
3.2.2 Challenges
3.2.2.1 Ambiguous Reimbursement Policies causing decrease in healthcare expenditure
3.2.3 Opportunities
3.2.3.1 Developing R&D technology leading to more target specific drugs and strong emerging pipeline
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Prostate Cancer Treatment Market

Chapter 4 Global Prostate Cancer Treatment Market Analysis, by Treatment
4.1 Introduction
4.2 Biological Therapy
4.2.1 Enzalutamid
4.2.2 Abiraterone
4.2.3 Leuprolide
4.2.4 Goserelin
4.2.5 Triptorelin
4.2.6 Histrelin
4.2.7 Degarelix
4.2.8 Sipuleucel-T
4.3 Chemotherapy
4.3.1 Mitotic inhibitors e.g. Docetaxel, Cabazitaxel
4.3.2 Topoisomerase inhibitors e.g. Mitoxantrone
4.3.3 Alkylating antineoplastic agent e.g. Estramustine

Chapter 5 Global Prostate Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of Latin America)
5.6 Middle East and Africa (United Arab Emirates, Saudi Arabia and Rest of Middle East and Africa)

Chapter 6 Company Profiles
6.1 Tolmar Inc.
6.2 Astellas Pharma, Inc.
6.3 AstraZeneca Plc
6.4 Ferring Pharmaceuticals
6.5 Johnson & Johnson
6.6 Abbott Laboratories
6.7 Sanofi
6.8 Ipsen
6.9 Novartis
6.10 Bayer Healthcare Pharmaceuticals, Inc

List Of Table : 

TABLE 1 Market Positioning of Key Players in Global Prostate Cancer Treatment Market
TABLE 2 Global Prostate Cancer Treatment Market, by Treatment, 2015 – 2025 (US$ Mn)
TABLE 3 Global Prostate Cancer Treatment Market, Biological Therapy, 2015 – 2025 (US$ Mn)
TABLE 4 Global Prostate Cancer Treatment Market, Chemotherapy, 2015 – 2025 (US$ Mn)
TABLE 5 Global Prostate Cancer Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 6 Tolmar Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 7 Astellas Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 8 AstraZeneca Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 9 Ferring Pharmaceuticals : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 10 Johnson & Johnson : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 11 Abbott Laboratories : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 12 Sanofi : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 13 Ipsen : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 14 Novartis : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 15 Bayer Healthcare Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

List Of Figure : 

FIG. 1 Prostate Cancer Treatment Market: Research Methodology
FIG. 2 Global Prostate Cancer Treatment Market, by Type of Treatment, 2016 (US$ Mn)
FIG. 3 Global Prostate Cancer Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Prostate Cancer Treatment Market, by Geography
FIG. 5 Enzalutamid Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 6 Abiraterone Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Leuprolide Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Goserelin Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Triptorelin Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Histrelin Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 11 Degarelix Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 12 Sipuleucel-T Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 13 Mitotic inhibitors Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 14 Topoisomerase inhibitors Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 15 Alkylating antineoplastic agent Market for Prostate Cancer treatment, 2015 – 2025 (US$ Mn)
FIG. 16 North America Prostate Cancer Treatment Market,2015 – 2025 (US$ Mn)
FIG. 17 Europe Prostate Cancer Treatment Market,  2015 – 2025 (US$ Mn)
FIG. 18 Asia Pacific Prostate Cancer Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 19 Latin America Prostate Cancer Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Middle East and Africa Prostate Cancer Treatment Market, 2015 – 2025 (US$ Mn)

The American Cancer Society (ACS) estimates that more than 12 million new cases of cancer are diagnosed worldwide each year. Around 99% of the cases for Prostate cancer is most commonly seen after the age of 50 years. Based on the treatment type, the Prostate cancer treatment market is segmented into:

  • Biological therapy
    • Enzalutamid
    • Abiraterone
    • Leuprolide
    • Goserelin
    • Triptorelin
    • Histrelin
    • Degarelix
    • Sipuleucel-T
  • Chemotherapy
    • Mitotic inhibitors e.g. Docetaxel, Cabazitaxel
    • Topoisomerase inhibitors e.g. Mitoxantrone
    • Alkylating antineoplastic agent e.g. Estramustine

According to market experts, biological therapy is the first line of treatment in order to reduce androgens in the body (Testosterone, Dihydrotestosterone) as they stimulate the growth of the prostate cancer cells. However, the drug related side effects are high, so patients are opting for chemotherapy where drugs such as docetaxel, cabazitaxel, mitoxantrone, and estramustine are prescribed for the treatment of prostate cancer. Chemotherapy is a treatment of choice to the patients who have become resistant to Biological therapy and the Prostate cancer has spread outside the Prostate gland and metastasized in distant organs. In base year 2016, biological therapy accounted for the major market share in the treatment followed by Chemotherapy. During the forecast period 2017-2025, targeted Biological therapy is expected to project a significant growth due to promising pipeline. The key factors assisting the segment growth were with enhanced reimbursement policies have increased the expenditure for the treatment in developed markets, rise in aging population coupled with growing public awareness, and technological advancement in the drug development with promising pipeline products for the treatment of Prostate cancer.

Prostate Cancer Treatment Market

or the purpose of this study, the global prostate cancer treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Prostate Cancer Treatment Market

North America was observed as the largest market for prostate cancer treatment in the base year 2016. According to American Cancer Society in 2017 there will be about 161,360 new cases of prostate cancer attributed mainly due to aging population and high public awareness of the disease has led to the early diagnosis and treatment for prostate cancer. Cancer Research UK states that prostate cancer accounts for 26% of all new cases of cancer in males. Europe is expected to be the second largest market due to rising public awareness related with early disease diagnosis, improved healthcare infrastructure, government and non-government organizations arranging awareness activities and camps, and supportive reimbursement policies. Newly approved drug molecules for treatment of pancreatic cancer have a good acceptance and penetration rate in the European market. Growth of Asia Pacific for prostate cancer treatment market is attributed by factors like rising prevalence of prostate cancer, increasing investments in R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care and aging population are going to fuel the rapid growth of prostate cancer treatment market in Latin America and Middle East and Africa region in the near future.   

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients